Sixty consecutive surviving patients treated with subdermal BCG (5 X 106f organisms) have been followed up for five years after resection of lung carcinoma. A control group of the previous 60 consecutive surviving patients not treated with BCG was similarly studied. We found no statistical evidence that the administration of BCG by the method described influenced the five-year survival rate, nor has any effective action upon involved lymph nodes or small metastases been demonstrated.
In 1974 we published (Edwards and Whitwell, 1974) an interim report on a series of 120 cases of resection for carcinoma of the lung operated upon by one surgeon. Sixty consecutive patients who survived the operation received BCG as a postoperative immunostimulant, and their survival was compared with that of the previous 60 consecutive surviving patients who were used as controls.
The method of administering BCG was by subdermal injection of 0 5 ml of BCG (Glaxo) (5X 106 organisms) in the deltoid region. This produced a local reaction, 2-3 cm diameter, which usually broke down to produce a series of sinuses or an ulcer, which persisted for four to six months.
All 120 cases have been followed up 
Survival rate
The overall survival rates of the control and BCG series are shown in Table 3 . The five-year survival rate of 20% for the particular control series selected was lower than the usually accepted figure (25 5% in the previous 180 surviving patients operated upon by the same surgeon), but the figures for the squamous-cell and adenocarcinoma survivals were virtually the same in the control and BCG series.
The type of resection did not materially influence the five-year survival (Table 4) .
In view of the possibility that BCG may have a more specific stimulant action upon macrophages and lymphocytes in invaded residual lymph nodes, the five-year survival of patients with and without histologically involved lymph nodes was compared (Table 5 ). These figures are analysed into the different histological types in Table 6 . No statistical difference is apparent in these two groups.
The survival for five years of two patients out of eight with oat-cell carcinoma after receiving BCG is of interest but of no significance when these small numbers are involved. 
